a:5:{s:8:"template";s:5073:" {{ keyword }}
{{ text }}
";s:4:"text";s:9337:"As part of the Summer program, you will be given priority consideration for the program’s full-time positions. for global audiences. Copyright © 2019 NBMBAA. Master of Educational Leadership with a strong emphasis in training and organizational development: ... Senior Executive Specialist Hematologic Malignancies at Janssen Oncology, Inc. Under Debi’s leadership the oncology team has executed several important transactions including the recent BCMA CAR-T/Legend deal, niraparib/TESARO, Imetelstat/Geron, and two deals with MacroGenics. NYSDOH review represents one of the most rigorous levels of validation nationally for such testing. Internships are available in the following functions: Product Brand Marketing with a focus on professional, consumer or payer campaigns, Market Access and Commercial Insights & Strategy. Learn More Our Leadership Team. The internship is a 12-week period during the Summer of 2021 and located in the greater Princeton, NJ or Philadelphia, PA area (depending on assignment). Clear and concise communication and presentation skills. With her guidance, the oncology team manages several significant alliances including the Ibrutinib alliance with Pharmacyclics/Abbie and Daratumumab with Genmab. ITEM CODE: CP-165558 | DATE OF PREPARATION: July 2020, This site uses cookies as described in our. Approximately 1.8 million people are expected to be diagnosed with cancer in the US in 2020, yet only a small percentage of adult patients participate in oncology clinical trials each year, despite clinical trials evaluating promising investigational therapies. Suboptimal patient recruitment is a significant rate-limiting factor in clinical trials that can lead to studies using excessive resources and time, and being underpowered or even abandoned. We are Janssen. Janssen has provided support for OncologyPRO since its inception. Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases Aug 19, 2020 $6.5 Billion Acquisition Through an All-Cash Tender Offer of $52.50 Per Momenta Share Debi also worked in the licensing group supporting the Neuroscience franchise and served in roles of increasing responsibility in the sales and marketing divisions of Janssen and Johnson & Johnson. With $76.5 billion in 2017 sales, Johnson & Johnson is the world's most comprehensive and broadly-based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices markets. Debi Watson is the head of the Oncology Business Development Group at Johnson & Johnson Innovation, Janssen Business Development, a position she has held since May 2013. Philadelphia Music Artists, Women's Fashion Boutique, Alcon Contact Lenses Review, Bathurst International 2020, Royal Brompton Hospital Departments, ";s:7:"expired";i:-1;}